Inovio Pharmaceuticals Lowered to Hold at Aegis (INO)

Inovio Pharmaceuticals (NYSE:INO) was downgraded by analysts at Aegis from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Friday, Stock Ratings Network reports. The analysts noted that the move was a valuation call.

Inovio Pharmaceuticals (NYSE:INO) opened at 1.59 on Friday. Inovio Pharmaceuticals has a one year low of $0.44 and a one year high of $3.03. The stock has a 50-day moving average of $1.43 and a 200-day moving average of $0.89. The company’s market cap is $287.6 million.

A number of other firms have also recently commented on INO. Analysts at Maxim Group raised their price target on shares of Inovio Pharmaceuticals from $1.00 to $2.00 in a research note to investors on Tuesday, July 9th. They now have a “buy” rating on the stock. Analysts at Zacks downgraded shares of Inovio Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note to investors on Wednesday, June 19th. They now have a $0.70 price target on the stock.

Inovio Pharmaceuticals, Inc, formerly Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of vaccines, called deoxyribonucleic acid (NYSE:INO) vaccines, focused on cancers and infectious diseases.



Latest News

Intellicheck Inc Expected to Post Q3 2020 Earnings of $0.00 Per Share
Intellicheck Inc Expected to Post Q3 2020 Earnings of $0.00 Per Share
Akero Therapeutics  Announces Quarterly  Earnings Results
Akero Therapeutics Announces Quarterly Earnings Results
Anexo Group  Announces Quarterly  Earnings Results
Anexo Group Announces Quarterly Earnings Results
The Watches of Switzerland Group  Releases Quarterly  Earnings Results, Beats Expectations By $0.90 EPS
The Watches of Switzerland Group Releases Quarterly Earnings Results, Beats Expectations By $0.90 EPS
Cassava Sciences  Announces  Earnings Results
Cassava Sciences Announces Earnings Results
Goodwin  Issues Quarterly  Earnings Results
Goodwin Issues Quarterly Earnings Results


 
© 2006-2020 Zolmax.